

ICD-10-CM Expert for Skilled Nursing Facilities and Inpatient Rehabilitation Facilities

The complete official guidelines and code set Codes valid from October 1, 2025 through September 30, 2026

Contents

	PICD-10-CM Expert for Skilled Nursing Facilities Part Rehabilitation Facilities 2026iii		Diseases of the Digestive System (KØØ-K95)727 Diseases of the Skin and Subcutaneous Tissue
		Chapter 12.	(LØØ-L99)755
	iii for 2026iii	Chapter 13.	Diseases of the Musculoskeletal System and
	or 2026		Connective Tissue (MØØ-M99)779
	orrect Codingiii	Chapter 14.	Diseases of Genitourinary System (NØØ-N99)871
	0-CM Guidelines for Coding and Reportingiii	Chapter 15.	Pregnancy, Childbirth, and the
	iii		Puerperium (OØØ-O9A)893
Index to	Diseases and Injuriesiii n Tableiii		Certain Conditions Originating in the Perinatal Period (PØØ-P96)933
Table of	Drugs and Chemicals	Chapter 17.	Congenital Malformations, Deformations, and Chromosomal Abnormalities (Q00-Q99)947
	tationsiv	Chapter 18.	
	of Diseasesv	Cl . 10	Findings, Not Elsewhere Classified (RØØ-R99)969
	d Code Descriptionsv	Chapter 19.	Injury, Poisoning, and Certain Other Consequences of External Causes (SØØ-T88)991
	Votationsv	Chanter 20	External Causes of Morbidity (V00-Y99)
Official N	otations v		Factors Influencing Health Status and Contact
	otations vi	Chapter 21.	with Health Services (200-Z99)
		Chapter 22.	Codes for Special Purposes (UØØ-U85)1307
	'S		
•	el Notations viii		esAppendixes–1
	Viii		Valid 3-character ICD-10-CM CodesAppendixes–1
illustrations		Appendix B:	Pharmacology List 2026Appendixes–3
	v for 2026 ix	Appendix C:	Z Codes for Long-Term Drug Use with Associated Drugs Appendixes–18
	tesix pdatesix	Appendix D:	Skilled Nursing Facility Patient-Driven
Proprietary 0	paatesx		Payment Model Appendixes – 20
Conversion	Table of ICD-10-CM Codesx	Appendix E:	PDPM Comorbid ConditionsAppendixes-23
		Appendix F:	PDPM Return-to-Provider Code List Appendixes–26
10 Steps to	Correct Coding xii	Appendix G:	Skilled Nursing Facility Active Diagnosis ListAppendixes-32
	Official Guidelines for	Annondiy H.	IRF Impairment Group Codes Appendixes – 34
Coding and	ReportingCoding Guidelines-1	1.1	
ICD-10-CM	Index to Diseases and Injuries1		IRF Comorbid ConditionsAppendixes-39 Coding Issues for Long-Term Care (LTC) Appendixes-45
ICD-10-CM	Neoplasm Table339		nsIllustrations-1
ICD-10-CM	Table of Drugs and Chemicals358	Chapter 3.	Diseases of the Blood and Blood-forming Organs
ICD-10-CIVI	Table of Drugs and Chemicals		and Certain Disorders Involving the Immune Mechanism (D50–D89)Illustrations–1
ICD-10-CM	Index to External Causes408		Red Blood Cells Illustrations–1
			White Blood Cell Illustrations–1
ICD-10-CM	Tabular List of Diseases and Injuries445		PlateletIllustrations-2
Chapter 1.	Certain Infectious and Parasitic Diseases (AØØ-B99),		CoagulationIllustrations–2 Spleen Anatomical Location and
•	UØ7.1, UØ9.9		External StructuresIllustrations—3
Chapter 2.	Neoplasms (CØØ-D49)471		Spleen Interior Structures Illustrations–3
Chapter 3.	Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the	Chapter 4.	Endocrine, Nutritional, and Metabolic Diseases (E00–E89) Illustrations–4
	Immune Mechanism (D5Ø-D89)513		Endocrine System Illustrations–4
Chapter 4.	Endocrine, Nutritional, and Metabolic Diseases (EØØ-E89)		ThyroidIllustrations–5 Thyroid and Parathyroid GlandsIllustrations–5
Chapter 5.	Mental, Behavioral and Neurodevelopmental		PancreasIllustrations–6 Anatomy of the Adrenal GlandIllustrations–6
Chamber C	Disorders (FØ1-F99)		Structure of an Ovary Illustrations–7
Chapter 6.	Diseases of the Nervous System (G00-G99)583		Testis and Associated Structures Illustrations-7
Chapter 7.	Diseases of the Eye and Adnexa (HØØ-H59)		Thymus Illustrations–8
Chapter 8.	Diseases of the Ear and Mastoid Process (H60-H95) 647		
Chapter 9. Chapter 10.	Diseases of the Circulatory System (IØØ-I99)661 Diseases of the Respiratory System (JØØ-J99), UØ7.Ø709		

ICD-10-CM 2026

Contents ICD-10-CM 2026

Chapter 6.	Diseases of the Nervous System (GØØ–G99)	Illustrations=9	Chapter 11.	Diseases of the Digestive System (KØØ–K95)	Illustrations=29
	Brain			Digestive System	
	Cranial Nerves			Omentum and Mesentery	
	Peripheral Nervous System			Peritoneum and Retroperitoneum	
	Spinal Cord and Spinal Nerves		Chapter 12	Diseases of the Skin and Subcutaneous	
	Nerve Cell		Chapter 12.	Tissue (LØØ–L99)	Illustrations_31
	Trigeminal and Facial Nerve			Nail Anatomy	
	Branches	Illustrations–12		Skin and Subcutaneous Tissue	
Chapter 7.	Diseases of the Eye and Adnexa		Cl . 13		11105110115-51
Chapter 7.	(HØØ–H59)	Illustrations_13	Chapter 13.	,	III
	Eye			and Connective Tissue (MØØ–M99)	
	Posterior Pole of Globe/Flow of	Illustrations—15		Bones and Joints	
	Aqueous Humor	Illustrations_13		Shoulder Anterior View	
	Lacrimal System	Illustrations 14		Shoulder Posterior View	
	Eye Musculature	Illustrations 14		Elbow Anterior View	
	Eyelid Structures			Elbow Posterior View	
Cl . 0		11103110113-14		Hand	
Chapter 8.	Diseases of the Ear and Mastoid			Hip Anterior View	
	Process (H6Ø–H95)			Hip Posterior View	
	Ear Anatomy	Illustrations–15		Knee Anterior View	
Chapter 9.	Diseases of the Circulatory			Knee Posterior View	
	System (IØØ–I99)	Illustrations–16		Foot	
	Anatomy of the Heart	Illustrations–16		Muscles	Illustrations – 35
	Heart Cross Section	Illustrations–16	Chapter 14.	Diseases of Genitourinary	
	Heart Valves	Illustrations–17		System (NØØ–N99)	Illustrations–36
	Heart Conduction System	Illustrations–17		Urinary System	
	Coronary Arteries			Male Genitourinary System	
	Arteries			Female Internal Genitalia	Illustrations–37
	Veins	Illustrations–20		Female Genitourinary Tract Lateral	
	Internal Carotid and Vertebral			View	Illustrations–37
	Arteries and Branches		Chapter 15.	Pregnancy, Childbirth, and the	
	External Carotid Artery and Branches			Puerperium (OØØ-O9A)	Illustrations-38
	Branches of Abdominal Aorta			Term Pregnancy – Single Gestation	Illustrations-38
	Portal Venous Circulation			Twin Gestation–Dichorionic–	
	Lymphatic System			Diamniotic (DI-DI)	Illustrations-38
	Axillary Lymph Nodes			Twin Gestation–Monochorionic–	
	Lymphatic System of Head and Neck	Illustrations–24		Diamniotic (MO-DI)	Illustrations-39
	Lymphatic Capillaries	Illustrations – 25		Twin Gestation–Monochorionic–	
	Lymphatic Drainage	Illustrations–25		Monoamniotic (MO-MO)	Illustrations-39
Chapter 10.	Diseases of the Respiratory		Chapter 19.	Injury, Poisoning, and Certain Other	
	System (JØØ–J99), UØ7.Ø	Illustrations-26		Consequences of External Causes	
	Respiratory System	Illustrations-26		(SØØ-T88)	Illustrations-40
	Upper Respiratory System	Illustrations-27		Types of Fractures	
	Lower Respiratory System	Illustrations-27		Salter-Harris Fracture Types	Illustrations=40
	Paranasal Sinuses				
	Lung Segments	Illustrations-28			
	Alveoli				
			1		

ii ICD-10-CM 2026

RP

ED

Age Edits

Newborn Age: 0

These diagnoses are intended for newborns and neonates and the patient's age must be 0 years.

N47.Ø Adherent prepuce, newborn

Pediatric Age: 0-17

These diagnoses are intended for children and the patient's age must be between 0 and 17 years.

L21.1 Seborrheic infantile dermatitis

Maternity Age: 9-64

These diagnoses are intended for childbearing patients between the age of 9 and 64 years.

OØ2.9 Abnormal product of conception, unspecified	RP M
---	------

Adult Age: 15-124

These diagnoses are intended for patients between the age of 15 and 124 years.

R54 Age-related physical debility Frailty Old age Senescence Senile asthenia Senile debility EXGLUDES 1 age-related cognitive decline (R41.81) sarcopenia (M62.84) senile psychosis (F03.-) senility NOS (R41.81)

Sex Edits

Effective April 1, 2024, the Integrated Outpatient Code Editor (IOCE), a program used to process claims for outpatient providers, has deactivated the sex conflict edit. There will no longer be a female or male edit restriction for ICD-10-CM codes.

Non-therapy Ancillary

This icon identifies diagnoses that are considered comorbid conditions for the non-therapy ancillary (NTA) payment component of the Patient Driven Payment Model (PDPM). For a comprehensive list of all NTA comorbidity diagnosis codes, please refer to appendix E, at the back of this book.

A31.0 Pulmonary mycobacterial infection Infection due to Mycobacterium avium Infection due to Mycobacterium intracellulare [Battey bacillus] Infection due to Mycobacterium kansasii

Speech-language Pathology

This icon identifies diagnoses that are considered comorbid conditions for the speech-language pathology (SLP) payment component of the Patient Driven Payment Model (PDPM). For a comprehensive list of all SLP comorbidity diagnosis codes, please refer to appendix E, at the back of this book.

```
CØ2.1 Malignant neoplasm of border of tongue

Malignant neoplasm of tip of tongue
```

Return to Provider

This icon identifies a diagnosis code that is unspecified, ambiguous, or is specified in the ICD-10-CM official coding guidelines and conventions to be inappropriate for reporting as the principal diagnosis. If one of these codes is reported as the principal diagnosis on the minimum data set (MDS), the MDS should be returned to the provider to select an appropriate ICD-10-CM code. For a comprehensive list of all return-to-provider codes, refer to appendix F, at the back of this book.

B90.0 Sequelae of central nervous system tuberculosis

IRF Etiologic Diagnosis

This icon identifies diagnoses that represent an etiologic diagnosis. The etiologic diagnosis, entered into Item 22 of the IRF-PAI, is the problem that led to the condition represented by the impairment group code (IGC), entered into Item 21 of the IRF-PAI. For a comprehensive list of impairment groups to which these etiologic diagnoses may be grouped, please refer to appendix H, at the back of this book.

G37.1 Central demyelination of corpus callosum

IRF Comorbid Condition

This icon identifies diagnoses that are considered comorbid conditions for an inpatient rehabilitation admission. When reported as secondary diagnoses, these conditions are recognized as having a significant impact on the cost of furnishing inpatient rehabilitation services, therefore qualifying a case for payment adjustment. Comorbid conditions are entered into Item 24 of the IRF PAI. For a comprehensive list of all comorbid conditions, please refer to appendix I, at the back of this book.

A32.89 Other forms of listeriosis Listerial cerebral arteritis

Color Bars

Manifestation Code

Codes defined as manifestation codes appear in italic type, with a blue color bar over the code description. A manifestation cannot be reported as a first-listed code; it is sequenced as a secondary diagnosis with the underlying disease code listed first.

G32.89 Other specified degenerative disorders of nervous system in diseases classified elsewhere

Degenerative encephalopathy in diseases classified elsewhere

Unspecified Diagnosis

Codes that appear with a gray color bar over the alphanumeric code identify unspecified diagnoses. These codes should be used in limited circumstances, when neither the diagnostic statement nor the documentation provides enough information to assign a more specific diagnosis code. The abbreviation NOS, "not otherwise specified," in the tabular list may be interpreted as "unspecified."

GØ3.9 Meningitis, unspecified Arachnoiditis (spinal) NOS RIC Excl: 03 Non-traumatic brain injury; 05 Non-traumatic spinal cord injury

ICD-10-CM 2026 vii

ICD-10-CM Index to Diseases and Injuries

A	Abnormal, abnormality, abnormalities — continued blood level — continued	Abnor cyto
	lithium R78.89	ā
Aarskog's syndrome Q87.19 Abandonment — see Maltreatment	magnesium R79.0 mineral NEC R79.0	
Abasia (-astasia) (hysterical) F44.4	zinc R79.0	
Abderhalden-Kaufmann-Lignac syndrome (cystinosis)	blood pressure	
E72.04 Abdomen, abdominal — see also condition	elevated RØ3.Ø low reading (nonspecific) RØ3.1	
acute R10.0	blood sugar R73.09	
angina K55.1	blood-gas level R79.81	
muscle deficiency syndrome Q79.4	bowel sounds R19.15	
Abdominalgia — see Pain, abdominal Abduction contracture, hip or other joint — see Contrac-	absent R19.11 hyperactive R19.12	
tion, joint	brain scan R94.02	
Aberrant (congenital) — see also Malposition, congenital	breathing RØ6.9	f
adrenal gland Q89.1	caloric test R94.138	al a vi
artery (peripheral) Q27.8 basilar NEC Q28.1	cerebrospinal fluid R83.9 cytology R83.6	darl den
cerebral Q28.3	drug level R83.2	dev
coronary Q24.5	enzyme level R83.Ø	
digestive system Q27.8	hormones R83.1 immunology R83.4	diag
eye Q15.8 lower limb Q27.8	microbiology R83.5	ĺ
precerebral Q28.1	nonmedicinal level R83.3	k
pulmonary Q25.79	specified type NEC R83.8	k
renal Q27.2 retina Q14.1	chemistry, blood R79.9 C-reactive protein R79.82	
specified site NEC Q27.8	drugs — see Findings, abnormal, in blood	
subclavian Q27.8	gas level R79.81	
upper limb Q27.8	minerals R79.Ø	9
vertebral Q28.1 breast Q83.8	pancytopenia D61.818 PTT R79.1	
endocrine gland NEC Q89.2	specified NEC R79.89	
hepatic duct Q44.5	toxins — see Findings, abnormal, in blood	i
pancreas Q45.3	chest sounds (friction) (rales) RØ9.89	
parathyroid gland Q89.2 pituitary gland Q89.2	chromosome, chromosomal Q99.9 with more than three X chromosomes, female Q97.1	
sebaceous glands, mucous membrane, mouth, congenital		l i
Q38.6	bronchial washings R84.8	r
spleen Q89.09	cerebrospinal fluid R83.8 cervix uteri NEC R87.89	r
subclavian artery Q27.8 thymus (gland) Q89.2	nasal secretions R84.8	
thyroid gland Q89.2	nipple discharge R89.8	9
vein (peripheral) NEC Q27.8	peritoneal fluid R85.89	9
cerebral Q28.3 digestive system Q27.8	pleural fluid R84.8 prostatic secretions R86.8	l t
lower limb Q27.8	saliva R85.89	
precerebral Q28.1	seminal fluid R86.8	dire
specified site NEC Q27.8	sputum R84.8 synovial fluid R89.8	ear
upper limb Q27.8 Aberration	throat scrapings R84.8	
distantial — see Disturbance, visual	vagina R87.89	
mental F99	vulva R87.89	Ebs
Abiotrophy P68 90	wound secretions R89.8 dicentric replacement Q93.2	ech
Abiotrophy R68.89 Ablatio, ablation	ring replacement Q93.2	ech ech
retinae — see Detachment, retina	sex Q99.8	elec
Ablepharia, ablepharon Q10.3	female phenotype Q97.9 specified NEC Q97.8	elec
Abnormal, abnormality, abnormalities — see also Anomaly	male phenotype Q98.9	elec elec
acid-base balance (mixed) E87.4	specified NEC Q98.8	elec
albumin R77.0	structural male Q98.6	elec
alphafetoprotein R77.2 alveolar ridge KØ8.9	specified NEC Q99.8 clinical findings NEC R68.89	elec
anatomical relationship Q89.9	coagulation D68.9	eryt
apertures, congenital, diaphragm Q79.1	newborn, transient P61.6	fece
atrial septal, specified NEC Q21.19	profile R79.1	find
auditory perception H93.29- ☑ diplacusis — <i>see</i> Diplacusis	time R79.1 communication — see Fistula	fluid
hyperacusis — see Hyperacusis	conjunctiva, vascular H11.41- ✓	
recruitment — see Recruitment, auditory	coronary artery Q24.5	F
threshold shift — see Shift, auditory threshold	cortisol-binding globulin E27.8	
autosomes Q99.9 fragile site Q95.5	course, eustachian tube Q17.8 creatinine clearance R94.4	F
basal metabolic rate R94.8	cytology	t
biosynthesis, testicular androgen E29.1	anus R85.619	
bleeding time R79.1	atypical squamous cells cannot exclude high grade	١
blood amino-acid level R79.83 blood level (of)	squamous intraepithelial lesion (ASC-H) R85.611	forn
cobalt R79.0	atypical squamous cells of undetermined signifi-	t
copper R79.0	cance (ASC-US) R85.610	l

```
mal, abnormality, abnormalities — continued
ology — continued
anus — continued
  high grade squamous intraepithelial lesion (HGSIL)
         R85.613
  human papillomavirus (HPV) DNA test
      high risk positive R85.81
      low risk postive R85.82
  inadequate smear R85.615
  low grade squamous intraepithelial lesion (LGSIL)
         R85.612
  satisfactory anal smear but lacking transformation
        zoné R85.616
   specified NEC R85.618
  unsatisfactory smear R85.615
     genital organs — see Abnormal, Papanicolaou
     (smear)
 adaptation curve H53.61
tofacial NEC — see Anomaly, dentofacial
elopment, developmental Q89.9
 entral nervous system Q07.9
 nostic imaging
abdomen, abdominal region NEC R93.5
biliary tract R93.2
bladder R93.41
breast R92.8
central nervous system NEC R90.89
cerebrovascular NEC R90.89
coronary circulation R93.1
digestive tract NEC R93.3
gastrointestinal (tract) R93.3
genitourinary organs R93.89
 ead R93.0
neart R93.1
ntrathoracic organ NEC R93.89
kidney R93.42- ▼
imbs R93.6
iver R93.2
ung (field) R91.8
musculoskeletal system NEC R93.7
renal pelvis R93.41
retroperitoneum R93.5
site specified NEC R93.89
skin and subcutaneous tissue R93.89
skull R93.Ø
testis R93.81- 🔽
ureter R93.41
urinary organs specified NEC R93.49
ection, teeth, fully erupted M26.30
ossicles, acquired NEC H74.39-
ankylosis — see Ankylosis, ear ossicles
discontinuity — see Discontinuity, ossicles, ear
partial loss — see Loss, ossicles, ear (partial)
tein Q22.5
ocardiogram R93.1
oencephalogram R90.81
ogram — see Abnormal, diagnostic imaging
ctrocardiogram [ECG] [EKG] R94.31
troencephalogram [EEG] R94.Ø1
ctrolyte — see Imbalance, electrolyte
ctromyogram [EMG] R94.131
ctro-oculogram [EOG] R94.110
ctrophysiological intracardiac studies R94.39
troretinogram [ERG] R94.111
throcytes
congenital, with perinatal jaundice D58.9
es (color) (contents) (mucus) R19.5
ling — see Findings, abnormal, without diagnosis
amniotic — see Abnormal, specimen, specified
cerebrospinal — see Abnormal, cerebrospinal fluid
peritoneal — see Abnormal, specimen, digestive or-
     gans
pleural — see Abnormal, specimen, respiratory organs synovial — see Abnormal, specimen, specified
thorax (bronchial washings) (pleural fluid) — see Ab-
     normal, specimen, respiratory organs
vaginal — see Abnormal, specimen, female genital
     organs
teeth KØØ.2
uterus — see Anomaly, uterus
```

cytologic evidence of malignancy R85.614

iron R79.Ø

Neoplasm Table

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior		Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic	≥ ₫	≥ ⅓	Ü	<u>~</u>	> <u>@</u>	⊃ &	Neoplasm, neoplastic	≥ ₫	≥ ଊ	Ü		⊃ ₫	⊃ ĕ
— continued							— continued						
brain — <i>continued</i> basal ganglia	C71.Ø	C79.31	_	D33.Ø	D43.Ø	D49.6	bronchus — continued main	C34.Ø- ✓	C78.Ø- ✓	DØ2.2- ▼	D14.3- ▼	D38.1	D49.1
cerebellopontine angle	C71.6	C79.31	_	D33.1	D43.1	D49.6	middle lobe of lung	C34.2	C78.Ø- ▼	DØ2.21	D14.31	D38.1	D49.1
cerebellum NOS	C71.6	C79.31	_	D33.1	D43.1	D49.6	overlapping		C/0.9-	002.21	וכ.דוט	D36.1	D49.1
cerebrum choroid plexus	C71.0 C71.7	C79.31 C79.31	_	D33.0 D33.1	D43.0 D43.1	D49.6 D49.6	lesion upper lobe of	C34.8- ▼	_	_	_	_	_
corpus callosum corpus striatum	C71.8 C71.0	C79.31 C79.31	_	D33.2 D33.0	D43.2 D43.0	D49.6 D49.6	lung	C34.1-	C78.Ø- ▼	DØ2.2-▼	D14.3-▼	D38.1	D49.1
cortex (cerebral)	C71.Ø	C79.31	_	D33.Ø	D43.Ø	D49.6	brow basal cell	C44.3Ø9	C79.2	DØ4.39	D23.39	D48.5	D49.2
frontal lobe globus pallidus	C71.1 C71.0	C79.31 C79.31	<u> </u>	D33.Ø D33.Ø	D43.0 D43.0	D49.6 D49.6	carcinoma specified type	C44.319	_	_	_	_	_
hippocampus	C71.2	C79.31	_	D33.Ø	D43.Ø	D49.6	NEC	C44.399	_	_	_	_	_
hypothalamus internal capsule	C71.0 C71.0	C79.31 C79.31	_	D33.Ø D33.Ø	D43.0 D43.0	D49.6 D49.6	squamous cell carcinoma	C44.329		_	_	_	_
medulla oblongata	C71.7	C79.31	_	D33.1	D43.1	D49.6	buccal (cavity)	CØ6.9 CØ6.Ø	C79.89 C79.89	DØØ.ØØ DØØ.Ø2	D1Ø.39 D1Ø.39	D37.Ø9 D37.Ø9	D49.Ø D49.Ø
meninges	C7Ø.Ø	C79.32	—	D32.Ø	D42.Ø	D49.7	commissure groove (lower)						
midbrain occipital lobe	C71.7 C71.4	C79.31 C79.31	_	D33.1 D33.0	D43.1 D43.0	D49.6 D49.6	(upper) mucosa	CØ6.1 CØ6.Ø	C79.89 C79.89	DØØ.Ø2 DØØ.Ø2	D10.39 D10.39	D37.Ø9 D37.Ø9	D49.Ø D49.Ø
overlapping							sulcus (lower)		Y				
lesion parietal lobe	C71.8 C71.3	C79.31 C79.31	_	 D33.0	D43.Ø	— D49.6	(upper) bulbourethral	CØ6.1	C79.89	DØØ.Ø2	D10.39	D37.Ø9	D49.Ø
peduncle pons	C71.7 C71.7	C79.31 C79.31	_	D33.1 D33.1	D43.1 D43.1	D49.6 D49.6	gland	C68.Ø	C79.19	DØ9.19	D3Ø.4	D41.3	D49.59
stem	C71.7	C79.31	_	D33.1	D43.1	D49.6	bursa — <i>see</i> Neoplasm, connective tissue						
tapetum temporal lobe	C71.8 C71.2	C79.31 C79.31	_	D33.2 D33.0	D43.2 D43.0	D49.6 D49.6	buttock NEC calf	C76.3 C76.5-▼	C79.89 C79.89	DØ4.5 DØ4.7- ✓	D36.7 D36.7	D48.7 D48.7	D49.89 D49.89
thalamus	C71.Ø	C79.31	_	D33.Ø	D43.Ø	D49.6	calvarium	C41.Ø	C79.51	_	D16.4	D48.Ø	D49.2
uncus ventricle (floor)	C71.2 C71.5	C79.31 C79.31	_	D33.Ø D33.Ø	D43.0 D43.0	D49.6 D49.6	calyx, renal	C65.	C79.Ø-₩	DØ9.19	D3Ø.1- ✓	D41.1- ☑	D49.51- ✓
fourth branchial (cleft) (cyst)	C71.7	C79.31		D33.1	D43.1	D49.6	anal	C21.1	C78.5	DØ1.3	D12.9	D37.8	D49.0
(vestiges)	C1Ø.4	C79.89	DØØ.Ø8	D1Ø.5	D37.05	D49.Ø	auditory (external) — see also						
breast (connective tissue) (glandular							Neoplasm, skin,	C44.2Ø- ▼	C70.2	DØ4.2- ▼	D23.2- ▼	D48.5	D49.2
tissue) (soft	6500 -	670.01	Dat M	D24 =	D40.6	Dio	ear auricular (external) —	C44.20-M	C/9.2	DØ4.2-V	D23.2- V	D46.5	D49.2
parts) areola	C5Ø.9- ✓ C5Ø.Ø- ✓	C79.81 C79.81	DØ5 ✓	D24 ✓ D24 ✓	D48.6- ✓ D48.6- ✓	D49.3 D49.3	<i>see also</i> Neoplasm, skin,						
axillary tail	C5Ø.6- ☑	C79.81	DØ5 ✓	D24M	D48.6-✓	D49.3	ear	C44.2Ø- ☑	C79.2	DØ4.2- ☑	D23.2- ✓	D48.5	D49.2
central portion inner	C5Ø.1- ✓ C5Ø.8- ✓	C79.81 C79.81	DØ5 ✓	D24✓ D24✓	D48.6-₩	D49.3 D49.3	canaliculi, biliary (biliferi)						
lower	C5Ø.8- ☑	C79.81	DØ5 ▼	D24 ✓	D48.6- ✓	D49.3	(intrahepatic) canthus (eye) (inner)	C22.1	C78.7	DØ1.5	D13.4	D37.6	D49.Ø
lower-inner quadrant	C5Ø.3- ▼	C79.81	DØ5₩	D24 ✓	D48.6-	D49.3	(outer)	C44.1Ø- ☑	C79.2	DØ4.1- ☑	D23.1- ▼	D48.5	D49.2
lower-outer quadrant	C5Ø.5- ▼	C79.81	DØ5₩	D24 ✓	D48.6- ▼	D49.3	basal cell carcinoma	C44.11- ✓	_	_	_	_	_
mastectomy site	C39.3 L2	(7).01	D03. L	D24.	D-10.0 12	545.5	sebaceous cell	C44.13- ☑	_	_	_	_	_
(skin) — see also Neoplasm, breast,						·	specified type NEC	C44.19- ✓	_	_	_	_	_
skin	C44.5Ø1	C79.2	- \			_	squamous cell carcinoma	C44.12- ▼					
specified as breast tissue	C5Ø.8- ▼	C79.81	_ \		_	_	capillary — see	C44.12-M	_		_		_
midline nipple	C5Ø.8-✓	C79.81	DØ5✓	D24 ✓	D48.6- ✓ D48.6- ✓	D49.3 D49.3	Neoplasm, connective tissue						
outer	C5Ø.8-	C79.81	DØ5	D24	D48.6-	D49.3 D49.3	caput coli	C18.Ø	C78.5	DØ1.Ø	D12.Ø	D37.4	D49.Ø
overlapping lesion	C5Ø.8- ▼	_		_	_	_	carcinoid — see Tumor, carcinoid						
skin	C44.5Ø1	C79.2	DØ4.5	D23.5	D48.5	D49.2	cardia (gastric) cardiac orifice	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.0
basal cell carcinoma	C44.511	_ <	_	_	_	_	(stomach)	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.Ø
specified type NEC	C44.591						cardio-esophageal junction	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.Ø
squamous cell	C44.591	_	_	_	_	_	cardio-esophagus carina (bronchus)	C16.Ø	C78.89	DØØ.2	D13.1	D37.1	D49.0
carcinoma tail (axillary)	C44.521 C5Ø.6- ☑	— C79.81	— DØ5 ▼	— D24 ▼	— D48.6- ▼	— D49.3	carotid (artery)	C34.Ø- ✓ C49.Ø	C78.Ø- ✓ C79.89	DØ2.2- ✓	D14.3- ✓ D21.Ø	D38.1 D48.1 ✓	D49.1 D49.2
upper	C5Ø.8- ☑	C79.81	DØ5 ▼	D24 ✓	D48.6- ☑	D49.3	body carpus (any bone)	C75.4 C4Ø.1- ▼	C79.89 C79.51	_	D35.5 D16.1- ▼	D44.6	D49.7
upper-inner quadrant	C5Ø.2- ▼	C79.81	DØ5 ▼	D24 ▼	D48.6- ✓	D49.3	cartilage (articular)	C4Ø.1-M	C/9.51	_	D10.1- V	_	_
upper-outer							(joint) NEC — see also Neoplasm,						
quadrant broad ligament	C5Ø.4- ✓ C57.1- ✓	C79.81 C79.82	DØ5 ✓ DØ7.39	D24 ✓ D28.2	D48.6- ✓ D39.8	D49.3 D49.59	bone	C41.9	C79.51		D16.9	D48.Ø	D49.2
bronchiogenic,							arytenoid auricular	C32.3 C49.0	C78.39 C79.89	DØ2.Ø	D14.1 D21.0	D38.Ø D48.1 ▼	D49.1 D49.2
bronchogenic (lung)		C78.Ø- ☑		D14.3- ▼	D38.1	D49.1	bronchi	C34.Ø- ✓	C78.39	_	D14.3- ✓	D38.1	D49.1
bronchiole bronchus	C34.9- ✓	C78.Ø- ✓	DØ2.2- ✓ DØ2.2- ✓	D14.3- ✓ D14.3- ✓	D38.1 D38.1	D49.1 D49.1	costal cricoid	C41.3 C32.3	C79.51 C78.39	 DØ2.Ø	D16.7 D14.1	D48.Ø D38.Ø	D49.2 D49.1
carina	C34.9- ✓	C78.Ø-₩	DØ2.2- V	D14.3- ☑	D38.1	D49.1 D49.1	cuneiform ear (external)	C32.3 C49.0	C78.39 C79.89	DØ2.Ø	D14.1 D21.0	D38.Ø D48.1 ☑	D49.1 D49.2
lower lobe of lung	C34.3- ▼	C78.Ø-▼	DØ2.2- ▼	D14.3- ▼	D38.1	D49.1	ensiform	C41.3	C79.51	_	D16.7	D48.Ø	D49.2
9					1		epiglottis	C32.1	C78.39	DØ2.Ø	D14.1	D38.Ø	D49.1

Table of Drugs and Chemicals

	lal)			ed				lal)			pe		
Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under- dosing	Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under- dosing
Androstalone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthiolimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Androstanolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthralin	T49.4X1	T49.4X2	T49.4X3	T49.4X4	T49.4X5	T49.4X6
Androsterone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthramycin	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	_	_	Antiadrenergic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Anesthesia	T41 2V1	T41 2V2	T41 2V2	T41 2V4	T41 2V5	T41 2V6	Antiallergic NEC	T45.ØX1	T45.ØX2	T45.ØX3	T45.0X4	T45.ØX5	T45.0X6
caudal endotracheal	T41.3X1 T41.0X1	T41.3X2 T41.0X2	T41.3X3 T41.0X3	T41.3X4 T41.0X4	T41.3X5 T41.0X5	T41.3X6 T41.0X6	Antiandrogen NEC Anti-anemic (drug)	T38.6X1	T38.6X2	T38.6X3 T45.8X3	T38.6X4 T45.8X4	T38.6X5 T45.8X5	T38.6X6 T45.8X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	(preparation)	143.671	143.072	143.003	143.004	143.683	143.000
inhalation	T41.ØX1	T41.ØX2	T41.ØX3	T41.ØX4	T41.ØX5	T41.ØX6	Antianxiety drug NEC	T43.5Ø1	T43.5Ø2	T43.5Ø3	T43.5Ø4	T43.5Ø5	T43.5Ø6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiaris toxicaria	T65.891	T65.892	T65.893	T65.894	_	_
mucosal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiarteriosclerotic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6	Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antibiotic Otic Suspension	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
plexus blocking potentiated	T41.3X1 T41.2Ø1	T41.3X2 T41.2Ø2	T41.3X3 T41.2Ø3	T41.3X4 T41.204	T41.3X5 T41.2Ø5	T41.3X6 T41.206	(Solution)* Antibiotic NEC	T36.91	T36.92	T36.93	T36.94	T36.95	T36.96
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	aminoglycoside	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	anticancer	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	antifungal	T36.7X1	T36.7X2	T36.7X3	T36.7X4	T36.7X5	T36.7X6
regional	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	antimycobacterial	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	antineoplastic	T45.1X1		T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anesthetic NEC — see also	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46	b-lactam NEC	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
Anesthesia	T/1 301	T/1 2/2	T/1 2/22	T/1 204	T41.205	T/1 200	cephalosporin (group)	T36.1X1	T36.1X2 T36.2X2	T36.1X3	T36.1X4 T36.2X4	T36.1X5 T36.2X5	T36.1X6 T36.2X6
with muscle relaxant general	T41.201 T41.201	T41.202 T41.202	T41.203 T41.203	T41.204 T41.204	T41.205	T41.206 T41.206	chloramphenicol (group) ENT	T36.2X1 T49.6X1	T49.6X2	T36.2X3 T49.6X3	T49.6X4	T49.6X5	T49.6X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	eye	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
gaseous NEC	T41.ØX1	T41.ØX2	T41.ØX3	T41.ØX4	T41.ØX5	T41.ØX6	fungicidal (local)	T49.ØX1	T49.ØX2	T49.0X3	T49.ØX4	T49.ØX5	T49.ØX6
general NEC	T41.201	T41.202	T41.2Ø3	T41.2Ø4	T41.205	T41.206	intestinal	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
halogenated hydrocarbon	T41.ØX1	T41.ØX2	T41.ØX3	T41.ØX4	T41.ØX5	T41.ØX6	local	T49.ØX1	T49.ØX2	T49.ØX3	T49.0X4	T49.ØX5	T49.ØX6
derivatives NEC			_,	_,	T4		macrolides	T36.3X1	T36.3X2	T36.3X3	T36.3X4	T36.3X5	T36.3X6
infiltration NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	polypeptide	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
intravenous NEC local NEC	T41.1X1 T41.3X1	T41.1X2 T41.3X2	T41.1X3 T41.3X3	T41.1X4 T41.3X4	T41.1X5 T41.3X5	T41.1X6	specified NEC tetracycline (group)	T36.8X1	T36.8X2 T36.4X2	T36.8X3 T36.4X3	T36.8X4 T36.4X4	T36.8X5 T36.4X5	T36.8X6 T36.4X6
rectal	T41.201	T41.202	T41.2Ø3	T41.204	T41.205	T41.206	throat	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	Anticancer agents NEC	T45.1X1	T45.0X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Anticholesterolemic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5		NEC						
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5		Anticholinergic NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
thiobarbiturate	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6	Anticholinesterase	T44.0X1	T44.ØX2	T44.ØX3	T44.0X4	T44.0X5	T44.0X6
topical Aneurine	T41.3X1 T45.2X1	T41.3X2 T45.2X2	T41.3X3 T45.2X3	T41.3X4 T45.2X4	T41.3X5 T45.2X5	T41.3X6	organophosphorus insecticide	T44.ØX1 T6Ø.ØX1	T44.0X2 T60.0X2	T44.0X3 T60.0X3	T44.0X4 T60.0X4	T44.ØX5	T44.ØX6
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6	nerve gas	T59.891	T59.892	T59.893	T59.894	_	_
Angio-Conray	T5Ø.8X1	T5Ø.8X2	T5Ø.8X3	T5Ø.8X4	T5Ø.8X5	T5Ø,8X6	reversible	T44.ØX1	T44.ØX2	T44.0X3	T44.ØX4	T44.ØX5	T44.ØX6
Angiotensin	T44.5X1	T44.5X2	T44.5X3	T44.5X4	T44.5X5	T44.5X6	ophthalmological	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
Angiotensinamide	T44.991	T44.992	T44.993	T44.994	T44.995	T44.996	Anticoagulant NEC	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516
Anhydrohydroxy-progesterone Anhydron	T38.5X1 T5Ø.2X1	T38.5X2 T50.2X2	T38.5X3 T5Ø.2X3	T38.5X4 T50.2X4	T38.5X5	T38.5X6 T50.2X6	Antagonist Anti-common-cold drug	T45.7X1 T48.5X1	T45.7X2	T45.7X3 T48.5X3	T45.7X4 T48.5X4	T45.7X5 T48.5X5	T45.7X6 T48.5X6
Anileridine	T40.491	T40.492	T40.493	T40.494	T40.495	T40.496	NEC NEC	140.57.1	140.372	140.575	140.574	140.585	140.570
Aniline (dye) (liquid)	T65.3X1	T65.3X2	T65.3X3	T65.3X4	-	_	Anticonvulsant	T42.71	T42.72	T42.73	T42.74	T42.75	T42.76
analgesic	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5		barbiturate	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
derivatives, therapeutic	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5	T39.1X6	combination (with	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
NEC vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4		_	barbiturate) hydantoin	T42.ØX1	T42.ØX2	T42.ØX3	T42.ØX4	T42.ØX5	T42.ØX6
Aniscoropine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	hypnotic NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
Anise oil	T47.5X1	T47.5X2	T47.5X3	T47.5X4	T47.5X5	T47.5X6	oxazolidinedione	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
Anisidine	T65.3X1	T65.3X2	T65.3X3	T65.3X4	_	_	pyrimidinedione	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516	specified NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
Anisotropine	T44.3X1	T44.3X2	144.3X3	T44.3X4	T44.3X5	T44.3X6	succinimide	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
methyl-bromide Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616	Antidepressant monoamine oxidase	T43.2Ø1 T43.1X1	T43.202 T43.1X2	T43.2Ø3 T43.1X3	T43.204 T43.1X4	T43.205 T43.1X5	T43.2Ø6 T43.1X6
Anorexiant (central)	T5Ø.5X1	T50.5X2	T5Ø.5X3	T5Ø.5X4	T5Ø.5X5	T5Ø.5X6	inhibitor	1.3.171	1.3.172	1 13.173	1 13.174	5.175	1 13.170
Anorexic agents	T5Ø.5X1		T5Ø.5X3	T5Ø.5X4	T5Ø.5X5	T50.5X6	selective serotonin	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
Ansaid*	T39.311	T39.312	T39.313	T39.314	T39.315	T39.316	norepinephrine reuptake		[
Ansamycin	T36.6X1		T36.6X3	T36.6X4	T36.6X5	T36.6X6	inhibitor						
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	— TEG (V5		selective serotonin reuptake	T43.221	T43.222	T43.223	T43.224	T43.225	T43.226
Antabuse	T50.6X1	T50.6X2	T5Ø.6X3	T5Ø.6X4	T5Ø.6X5 T47.1X5	T5Ø.6X6	inhibitor specified NEC	T42 201	T42 202	T42 202	T43.294	T/2 205	T42 204
Antacid NEC Antagonist	T47.1X1	T47.1X2	T47.1X3	T47.1X4	147.133	T47.1X6	tetracyclic	T43.291 T43.021	T43.292 T43.022	T43.293 T43.023	T43.294	T43.295 T43.025	T43.296 T43.026
Aldosterone	T5Ø.ØX1	T5Ø.ØX2	T5Ø.ØX3	T5Ø.ØX4	T5Ø.ØX5	T5Ø.ØX6	triazolopyridine	T43.211	T43.022	T43.213	T43.214	T43.215	T43.216
alpha-adrenoreceptor	T44.6X1	T44.6X2	T44.6X3	T44.6X4	T44.6X5	T44.6X6	tricyclic	T43.Ø11	T43.Ø12	T43.Ø13	T43.Ø14	T43.Ø15	T43.Ø16
anticoagulant	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6	Antidiabetic NEC	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6	biguanide	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	and sulfonyl combined	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
folic acid H2 receptor	T45.1X1 T47.ØX1	T45.1X2 T47.ØX2	T45.1X3 T47.ØX3	T45.1X4 T47.ØX4	T45.1X5 T47.ØX5	T45.1X6 T47.ØX6	combined sulfonylurea	T38.3X1	T38.3X2 T38.3X2	T38.3X3 T38.3X3	T38.3X4 T38.3X4	T38.3X5 T38.3X5	T38.3X6 T38.3X6
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6	Antidiarrheal drug NEC	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
narcotic analgesic	T5Ø.7X1	T50.7X2	T5Ø.7X3	T5Ø.7X4	T50.7X5	T50.7X6	absorbent	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
opiate	T5Ø.7X1	T50.7X2	T5Ø.7X3	T5Ø.7X4	T50.7X5	T50.7X6	Anti-D immunoglobulin	T5Ø.Z11	T5Ø.Z12	T5Ø.Z13	T5Ø.Z14	T5Ø.Z15	T5Ø.Z16
pyrimidine	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6	(human)						
serotonin	T46.5X1	T46.5X2	T46.5X3	T46.5X4	T46.5X5	T46.5X6	Antidiphtheria serum	T5Ø.Z11	T50.Z12	T5Ø.Z13	T5Ø.Z14	T5Ø.Z15	T5Ø.Z16
Antazolin (e)	T45.ØX1	T45.ØX2	T45.ØX3	T45.ØX4	T45.ØX5	T45.0X6	Antidiuretic hormone	T38.891	T38.892	T38.893	T38.894	T38.895	T38.896
Anterior pituitary hormone NEC	T38.811	T38.812	T38.813	T38.814	T38.815	T38.816	Antidote NEC heavy metal	T5Ø.6X1 T45.8X1	T5Ø.6X2 T45.8X2	T5Ø.6X3 T45.8X3	T5Ø.6X4 T45.8X4	T5Ø.6X5 T45.8X5	T5Ø.6X6 T45.8X6
Anthelmintic NEC	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6	Antidysrhythmic NEC	T46.2X1		T46.2X3			T46.2X6
		. '	'	'			•		. '		'		

רט- ו	O-CIV	2020			Chapter 2. N	eopiasms		CØ2.4-C	ב.שו.
		CØ2.4	Maligna	nt neoplasm of lingual tonsil malignant neoplasm of tonsil NOS (CØ	(9.9)	CØ7	_	nant neoplasm of parotid gland additional code to identify:	
		CØ2.8	Maligna	nt neoplasm of overlapping sites of ton	gue SL		alc	cohol abuse and dependence (F10) posure to environmental tobacco smoke (Z77.22)	
		CØ2 9		ant neoplasm of two or more contiguous s nt neoplasm of tongue, unspecified	ites of tongue			posure to environmental tobacco smoke (277.22) posure to tobacco smoke in the perinatal period (P96.81)	
√4th	CØ3		-	olasm of gum	32			tory of tobacco dependence (Z87.891)	
	CDJ	INCL	-	alignant neoplasm of alveolar (ridge) mucc	osa			cupational exposure to environmental tobacco smoke (Z57.31) pacco dependence (F17)	1
			m	alignant neoplasm of gingiva				pacco use (Z72.Ø)	
				code to identify:		√ 4 th CØ8	Malign	nant neoplasm of other and unspecified major salivary gla	and
				e and dependence (F1Ø) Pacco dependence (Z87.891)				malignant neoplasm of salivary ducts	
		tok	oacco depe	endence (F17)				additional code to identify: cohol abuse and dependence (F1Ø)	
			oacco use	(<mark>Z72.Ø)</mark> alignant odontogenic neoplasms (C41.Ø-C41	7)			posure to environmental tobacco smoke (Z77.22)	
				nt neoplasm of upper gum	.1) SL			posure to tobacco smoke in the perinatal period (P96.81)	
				nt neoplasm of lower gum	SL			story of tobacco dependence (Z87.891) cupational exposure to environmental tobacco smoke (Z57.31)	١
		CØ3.9	Maligna	nt neoplasm of gum, unspecified	SL			pacco dependence (F17)	,
$\sqrt{4}$ th	CØ4	Malign	nant neop	olasm of floor of mouth				pacco use (Z72.0)	
				code to identify:			EXCLU	malignant neoplasms of specified minor salivary glands v are classified according to their anatomical location	
				e and dependence (F1Ø) Pacco dependence (Z87.891)			EXCLU	malignant neoplasms of minor salivary glands NOS (CØ6	
				endence (F17)				malignant neoplasm of parotid gland (CØ7)	,
			oacco use (CØ8.Ø	Malignant neoplasm of submandibular gland	
		CØ4.Ø		nt neoplasm of anterior floor of mouth ant neoplasm of anterior to the premolar-c	SL		C00 1	Malignant neoplasm of submaxillary gland Malignant neoplasm of sublingual gland	
		CØ4.1	,	ant neoplasm of lateral floor of mouth	SL SL			Malignant neoplasm of major salivary gland, unspecified	d
			_	nt neoplasm of overlapping sites of floo			\neg	Malignant neoplasm of salivary gland (major) NOS	
			mouth		SL	√4 th CØ9	Malig	nant neoplasm of tonsil	
_				nt neoplasm of floor of mouth, unspecif	fied 💴			additional code to identify:	
√4 th	CØ5	-	-	plasm of palate		,		ohol abuse and dependence (F10) posure to environmental tobacco smoke (Z77.22)	
				code to identify: e and dependence (F1Ø)				posure to tobacco smoke in the perinatal period (P96.81)	
		his	tory of tob	pacco dependence (Z87.891)				story of tobacco dependence (Z87.891)	
				endence (F17)				cupational exposure to environmental tobacco smoke (Z57.31) pacco dependence (F17)	1
			Dacco use (posi's sarcoma of palate (C46.2)				pacco use (Z72.Ø)	
				nt neoplasm of hard palate	SL		EXCLU	malignant neoplasm of lingual tonsil (CØ2.4)	
		CØ5.1		nt neoplasm of soft palate	SL		C00 0	malignant neoplasm of pharyngeal tonsil (C11.1)	SL
			EXCLUDE	malignant neoplasm of nasopharynge soft palate (C11.3)	eal surface of		CØ9.Ø	Malignant neoplasm of tonsillar fossa Malignant neoplasm of tonsillar pillar (anterior)	31
		CØ5.2	Maligna	nt neoplasm of uvula	SL			(posterior)	SL
				nt neoplasm of overlapping sites of pala	ate 🗓		CØ9.8	3	SL
			Maligna	nt neoplasm of palate, unspecified	SL		CØ9.9	Malignant neoplasm of tonsil, unspecified Malignant neoplasm of faucial tonsils	SL
			_	ant neoplasm of roof of mouth				Malignant neoplasm of palatine tonsils	
√4 th	CØ6	-		plasm of other and unspecified parts of	mouth			Malignant neoplasm of tonsil NOS	
				code to identify: e and dependence (F1Ø)		√4 th C1Ø	_	nant neoplasm of oropharynx	
				acco dependence (Z87.891)				additional code to identify: cohol abuse and dependence (F1Ø)	
				endence (F17)				posure to environmental tobacco smoke (Z77.22)	
		1	Maligna	nt neoplasm of cheek mucosa	SL		ex	posure to tobacco smoke in the perinatal period (P96.81)	
		CD0.D		ant neoplasm of buccal mucosa NOS				story of tobacco dependence (Z87.891)	`
			Malign	ant neoplasm of internal cheek				cupational exposure to environmental tobacco smoke (Z57.31) pacco dependence (F17)	1
		CØ6.1	_	nt neoplasm of vestibule of mouth	SL			pacco use (Z72.Ø)	
			_	ant neoplasm of buccal sulcus (upper) (low ant neoplasm of labial sulcus (upper) (lowe				IDES 2 malignant neoplasm of tonsil (CØ9)	
		CØ6.2		nt neoplasm of retromolar area	SL			: Oropharynx: Middle portion of pharynx (throat); communicates oral cavity, nasopharynx and laryngopharynx.	witr
	$\sqrt{5}^{th}$	CØ6.8		nt neoplasm of overlapping sites of oth	er and			Malignant neoplasm of vallecula	SL
				ied parts of mouth Malignant neoplasm of overlapping si	tes of		C1Ø.1	Malignant neoplasm of anterior surface of epiglottis	SL
				unspecified parts of mouth	SL			Malignant neoplasm of epiglottis, free border [margin] Malignant neoplasm of glossoepiglottic fold(s)	
			CØ6.89	Malignant neoplasm of overlapping si				EXCLUDES 2 malignant neoplasm of epiglottic folia(s)	rtion
				parts of mouth "book leaf" neoplasm [ventral surface o	f tongue and			NOS (C32.1)	
				floor of mouth]	. 5===			Malignant neoplasm of lateral wall of oropharynx	SL
		CØ6.9		nt neoplasm of mouth, unspecified	SL			Malignant neoplasm of posterior wall of oropharynx	SL
			_	ant neoplasm of minor salivary gland, unsp ant neoplasm of oral cavity NOS	pecified site		C1Ø.4	Malignant neoplasm of branchial cleft Malignant neoplasm of branchial cyst [site of neoplasm]	SL
			ivialigh	ant neoplasin of oral cavity 1103			C1Ø.8	Malignant neoplasm of overlapping sites of oropharynx	SL
								Malignant neoplasm of junctional region of oropharynx	_
							C1Ø.9	Malignant neoplasm of oropharynx, unspecified	SL

585

GØ4 Encephalitis, myelitis and encephalomyelitis GØ4.9 Encephalitis, myelitis and encephalomyelitis, unspecified **INCLUDES** acute ascending myelitis GØ4.9Ø Encephalitis and encephalomyelitis, meningoencephalitis unspecified Ventriculitis (cerebral) NOS meningomyelitis EXCLUDES 1 RIC Excl: 03 Non-traumatic brain injury encephalopathy NOS (G93.40) GØ4.91 Myelitis, unspecified ED CC EXCLUDES 2 acute transverse myelitis (G37.3) RIC Excl: 03 Non-traumatic brain injury alcoholic encephalopathy (G31.2) GØ5 Encephalitis, myelitis and encephalomyelitis in diseases classified multiple sclerosis (G35) elsewhere myalgic encephalomyelitis (G93.32) Code first underlying disease, such as: subacute necrotizing myelitis (G37.4) $congenital \ to xoplasmos is \ encephalitis, \ myelitis \ and \ encephalomy elitis$ toxic encephalitis (G92.8) toxic encephalopathy (G92.8) cytomegaloviral encephalitis, myelitis and encephalomyelitis (B25.8) **DEF:** Encephalitis: Inflammation of the brain, often caused by viral or encephalitis, myelitis and encephalomyelitis (in) systemic lupus bacterial infection. ervthematosus (M32.19) **DEF:** Encephalomyelitis: Inflammatory disease, often viral in nature, that eosinophilic meningoencephalitis (B83.2) affects the brain and spinal cord. human immunodeficiency virus [HIV] disease (B2Ø) **DEF:** Myelitis: Inflammation of the spinal cord. poliovirus (A8Ø.-) GØ4.Ø Acute disseminated encephalitis and encephalomyelitis (ADEM) suppurative otitis media (H66.Ø1-H66.4) **EXCLUDES 1** acute necrotizing hemorrhagic encephalopathy systemic lupus erythematosus (M32.19) (GØ4.3-) trichinellosis (B75) other noninfectious acute disseminated **EXCLUDES 1** adenoviral encephalitis, myelitis and encephalomyelitis (A85.1) encephalomyelitis (noninfectious ADEM) (GØ4.81) encephalitis, myelitis and encephalomyelitis (in) measles (BØ5.0) GØ4.00 Acute disseminated encephalitis and enteroviral encephalitis, myelitis and encephalomyelitis (A85.Ø) encephalomyelitis, unspecified RIC Excl: 03 Non-traumatic brain injury herpesviral [herpes simplex] encephalitis, myelitis and Postinfectious acute disseminated encephalitis and encephalomyelitis (BØØ.4) GØ4.Ø1 encephalomyelitis (postinfectious ADEM) listerial encephalitis, myelitis and encephalomyelitis (A32.12) **EXCLUDES 1** post chickenpox encephalitis (BØ1.1) meningococcal encephalitis, myelitis and encephalomyelitis post measles encephalitis (BØ5.Ø) (A39.81) post measles myelitis (BØ5.1) mumps encephalitis, myelitis and encephalomyelitis (B26.2) RIC Excl: 03 Non-traumatic brain injury postchickenpox encephalitis, myelitis and encephalomyelitis GØ4.02 Postimmunization acute disseminated encephalitis, myelitis and encephalomyelitis rubella encephalitis, myelitis and encephalomyelitis (BØ6.Ø1) Encephalitis, post immunization toxoplasmosis encephalitis, myelitis and encephalomyelitis Encephalomyelitis, post immunization Use additional code to identify the vaccine (T50.Azoster encephalitis, myelitis and encephalomyelitis (BØ2.Ø) T5Ø.B-, T5Ø.Z-) 605.3 Encephalitis and encephalomyelitis in diseases classified GØ4.1 Tropical spastic paraplegia elsewhere GØ4.2 Bacterial meningoencephalitis and meningomyelitis, not Meningoencephalitis in diseases classified elsewhere elsewhere classified Code first underlying disease RIC Excl: 03 Non-traumatic brain injury; 05 Non-traumatic spinal GØ5.4 Myelitis in diseases classified elsewhere RP ED CC cord injury Meningomyelitis in diseases classified elsewhere GØ4.3 Acute necrotizing hemorrhagic encephalopathy RIC Excl: 03 Non-traumatic brain injury **EXCLUDES 1** acute disseminated encephalitis and encephalomyelitis GØ6 Intracranial and intraspinal abscess and granuloma (GØ4.Ø-) GØ4.3Ø Acute necrotizing hemorrhagic encephalopathy, Use additional code (B95-B97) to identify infectious agent **DEF:** Abscess: Circumscribed collection of pus resulting from bacteria, unspecified frequently associated with swelling and other signs of inflammation. RIC Excl: 03 Non-traumatic brain injury Postinfectious acute necrotizing hemorrhagic **DEF:** Granuloma: Abnormal, dense collections of cells forming a mass or GØ4.31 nodule of chronically inflamed tissue with granulations that is usually ED CC encephalopathy associated with an infective process. RIC Excl: 03 Non-traumatic brain injury ED CC GØ6.Ø Intracranial abscess and granuloma GØ4.32 Postimmunization acute necrotizing hemorrhagic Brain [any part] abscess (embolic) encephalopathy Cerebellar abscess (embolic) additional code to identify the vaccine (T5Ø.A-, Cerebral abscess (embolic) T5Ø.B-, T5Ø.Z-) Intracranial epidural abscess or granuloma GØ4.39 Other acute necrotizing hemorrhagic encephalopathy ED CC Intracranial extradural abscess or granuloma Code also underlying etiology, if applicable RIC Excl. 03 Non-traumatic brain injury Intracranial subdural abscess or granuloma Otogenic abscess (embolic) GØ4.8 Other encephalitis, myelitis and encephalomyelitis **EXCLUDES 1** tuberculous intracranial abscess and granuloma (A17.81) Code also any associated seizure (G40,-, R56,9) RIC Excl: 03 Non-traumatic brain injury GØ4.81 Other encephalitis and encephalomyelitis GØ6.1 Intraspinal abscess and granuloma ED CC Noninfectious acute disseminated encephalomyelitis Abscess (embolic) of spinal cord [any part] (noninfectious ADEM) Intraspinal epidural abscess or granuloma RIC Excl: 03 Non-traumatic brain injury Intraspinal extradural abscess or granuloma GØ4.82 Acute flaccid myelitis ED CC Intraspinal subdural abscess or granuloma **EXCLUDES 1** transverse myelitis (G37.3) **EXCLUDES 1** tuberculous intraspinal abscess and granuloma AHA: 2021,4Q,11 (A17.81) RIC Excl: 03 Non-traumatic brain injury RIC Excl: 03 Non-traumatic brain injury ED CC GØ4.89 Other myelitis Extradural and subdural abscess, unspecified AHA: 2020,1Q,14 RIC Excl: 03 Non-traumatic brain injury RIC Excl: 03 Non-traumatic brain injury

Chapter 9. Diseases of the Circulatory System (IØØ–I99)

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

a. Hypertension

The classification presumes a causal relationship between hypertension and heart involvement and between hypertension and kidney involvement, as the two conditions are linked by the term "with" in the Alphabetic Index. These conditions should be coded as related even in the absence of provider documentation explicitly linking them, unless the documentation clearly states the conditions are unrelated.

For hypertension and conditions not specifically linked by relational terms such as "with," "associated with" or "due to" in the classification, provider documentation must link the conditions in order to code them as related.

1) Hypertension with heart disease

Hypertension with heart conditions classified to 150.- or 151.4–151.7, 151.89, 151.9, are assigned to a code from category 111, Hypertensive heart disease. Use additional code(s) from category 150, Heart failure, to identify the type(s) of heart failure in those patients with heart failure. The same heart conditions (150.-, 151.4–151.7, 151.89, 151.9) with hypertension are coded separately if the provider has documented they are unrelated to the hypertension. Sequence according to the circumstances of the admission/encounter.

Patient is admitted in left heart failure. Patient also has a history of hypertension managed by medication.

I11.Ø Hypertensive heart disease with heart failure

150.1 Left ventricular failure, unspecified

Explanation: Without a diagnostic statement to the contrary, hypertension and heart failure have an assumed causal relationship, and a combination code should be used. An additional code to identify the type of heart failure (I5Ø.-) should also be provided.

2) Hypertensive chronic kidney disease

Assign codes from category I12, Hypertensive chronic kidney disease, when both hypertension and a condition classifiable to category N18, Chronic kidney disease (CKD), are present. CKD should not be coded as hypertensive if the provider indicates the CKD is not related to the hypertension.

The appropriate code from category N18 should be used as a secondary code with a code from category 112 to identify the stage of chronic kidney disease.

See Section I.C.14. Chronic kidney disease.

If a patient has hypertensive chronic kidney disease and acute renal failure, the acute renal failure should also be coded. Sequence according to the circumstances of the admission/encounter.

Patient is admitted with stage IV chronic kidney disease (CKD) due to polycystic kidney disease. Patient also is on lisinopril for hypertension.

N18.4 Chronic kidney disease, stage 4 (severe)

Q61.3 Polycystic kidney, unspecified

I10 Essential (primary) hypertension

Explanation: A combination code describing a relationship between hypertension and CKD is not used because the physician documentation identifies the polycystic kidney disease as the cause for the CKD.

3) Hypertensive heart and chronic kidney disease

Assign codes from combination category I13, Hypertensive heart and chronic kidney disease, when there is hypertension with both heart and kidney involvement. If heart failure is present, assign an additional code from category I50 to identify the type of heart failure.

The appropriate code from category N18, Chronic kidney disease, should be used as a secondary code with a code from category I13 to identify the stage of chronic kidney disease.

See Section I.C.14. Chronic kidney disease.

The codes in category I13, Hypertensive heart and chronic kidney disease, are combination codes that include hypertension, heart disease and chronic kidney disease. The Includes note at I13 specifies that the

conditions included at I11 and I12 are included together in I13. If a patient has hypertension, heart disease and chronic kidney disease, then a code from I13 should be used, not individual codes for hypertension, heart disease and chronic kidney disease, or codes from I11 or I12. For patients with both acute renal failure and chronic kidney disease, the acute renal failure should also be coded. Sequence according to the circumstances of the admission/encounter.

Hypertensive heart and kidney disease with congestive heart failure and stage 2 chronic kidney disease

I13.Ø Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease

150.9 Heart failure, unspecified

N18.2 Chronic kidney disease, stage 2 (mild)

Explanation: Combination codes in category I13 are used to report conditions classifiable to both categories I11 and I12. Do not report conditions classifiable to I11 and I12 separately. Use additional codes to report type of heart failure and stage of CKD.

4) Hypertensive cerebrovascular disease

For hypertensive cerebrovascular disease, first assign the appropriate code from categories 160–169, followed by the appropriate hypertension code.

5) Hypertensive retinopathy

Subcategory H35.0, Background retinopathy and retinal vascular changes, should be used along with a code from categories I10–I15, in the Hypertensive diseases section, to include the systemic hypertension. The sequencing is based on the reason for the encounter.

Hypertensive retinopathy of the right eye

H35.Ø31 Hypertensive retinopathy, right eye Essential (primary) hypertension

Explanation: Hypertensive retinopathy requires two codes: the appropriate subcategory H35.0 code and a code for the hypertension.

6) Hypertension, secondary

Secondary hypertension is due to an underlying condition. Two codes are required: one to identify the underlying etiology and one from category I15 to identify the hypertension. Sequencing of codes is determined by the reason for admission/encounter.

Renovascular hypertension due to renal artery atherosclerosis

I15.Ø Renovascular hypertension

170.1 Atherosclerosis of renal artery

Explanation: Secondary hypertension requires two codes: a code to identify the etiology and the appropriate I15 code.

7) Hypertension, transient

Assign code RØ3.Ø, Elevated blood pressure reading without diagnosis of hypertension, unless patient has an established diagnosis of hypertension. Assign code O13.-, Gestational [pregnancy-induced] hypertension without significant proteinuria, or O14.-, Pre-eclampsia, for transient hypertension of pregnancy.

8) Hypertension, controlled

This diagnostic statement usually refers to an existing state of hypertension under control by therapy. Assign the appropriate code from categories I10–I15, Hypertensive diseases.

9) Hypertension, uncontrolled

Uncontrolled hypertension may refer to untreated hypertension or hypertension not responding to current therapeutic regimen. In either case, assign the appropriate code from categories I10–I15, Hypertensive diseases.

10) Hypertensive crisis

Assign a code from category I16, Hypertensive crisis, for documented hypertensive urgency, hypertensive emergency or unspecified hypertensive crisis. Code also any identified hypertensive disease (I10–I15). The sequencing is based on the reason for the encounter.

ICD-10-CM 2026 661

L97.908-L98.499	Chapter 12. Diseases of the S	kin and Subcutaneous Tissue	ICD-10-CM 2026
	L97.908 Non-pressure chronic ulcer of unspecified part of unspecified lower leg with other specified severity	L98.4 Non-press	lic cellulitis [Wells] ure chronic ulcer of skin, not elsewhere classified
	L97.909 Non-pressure chronic ulcer of unspecified part of unspecified lower leg with unspecified severity		ulcer of skin NOS ulcer NOS skin NOS
<mark>√6th L97.91</mark>	Non-pressure chronic ulcer of unspecified part of	EXCLUDES	3 3 . ,
	right lower leg		pressure ulcer (pressure area) (L89)
	L97.911 Non-pressure chronic ulcer of unspecified		skin infections (LØØ-LØ8)
	part of right lower leg limited to breakdown of skin		specific infections classified to AØØ-B99
	L97.912 Non-pressure chronic ulcer of unspecified		ulcer of lower limb NEC (L97)
	part of right lower leg with fat layer	AUA-20	varicose ulcer (183.Ø-183.93)
	exposed	AHA: 20	depth and/or severity of a diagnosed nonpressure ulcer
	L97.913 Non-pressure chronic ulcer of unspecified part of right lower leg with necrosis of muscle	can be de clinician:	etermined based on medical record documentation from swho are not the patient's provider.
	L97.914 Non-pressure chronic ulcer of unspecified	√6 th L98.41 I	lon-pressure chronic ulcer of buttock
	part of right lower leg with necrosis of		L98.411 Non-pressure chronic ulcer of buttock
	bone ED		limited to breakdown of skin 198.412 Non-pressure chronic ulcer of buttock with
	L97.915 Non-pressure chronic ulcer of unspecified part of right lower leg with muscle	l '	rat layer exposed
	involvement without evidence of		L98.413 Non-pressure chronic ulcer of buttock with
	necrosis		necrosis of muscle
	L97.916 Non-pressure chronic ulcer of unspecified part of right lower leg with bone		L98.414 Non-pressure chronic ulcer of buttock with necrosis of bone
	involvement without evidence of		L98.415 Non-pressure chronic ulcer of buttock with
	necrosis		muscle involvement without evidence of
	L97.918 Non-pressure chronic ulcer of unspecified		necrosis
	part of right lower leg with other specified severity		L98.416 Non-pressure chronic ulcer of buttock with
	L97.919 Non-pressure chronic ulcer of unspecified		bone involvement without evidence of necrosis.
	part of right lower leg with unspecified		98.418 Non-pressure chronic ulcer of buttock with
	severity		other specified severity
√6 th L97.92	Non-pressure chronic ulcer of unspecified part of left		198.419 Non-pressure chronic ulcer of buttock with
	lower leg L97.921 Non-pressure chronic ulcer of unspecified		unspecified severity 🗈
	part of left lower leg limited to breakdown		Non-pressure chronic ulcer of back
	of skin		L98.421 Non-pressure chronic ulcer of back limited
	L97.922 Non-pressure chronic ulcer of unspecified		to breakdown of skin 198.422 Non-pressure chronic ulcer of back with
	part of left lower leg with fat layer exposed		fat layer exposed
	L97.923 Non-pressure chroniculcer of unspecified		L98.423 Non-pressure chronic ulcer of back with
	part of left lower leg with necrosis of		necrosis of muscle
	muscle		L98.424 Non-pressure chronic ulcer of back with
	L97.924 Non-pressure chronic ulcer of unspecified part of left lower leg with necrosis of		necrosis of bone 198.425 Non-pressure chronic ulcer of back with
	bone		muscle involvement without evidence of
	L97.925 Non-pressure chronic ulcer of unspecified		necrosis
	part of left lower leg with muscle		L98.426 Non-pressure chronic ulcer of back with
	involvement without evidence of		bone involvement without evidence of necrosis
	L97.926 Non-pressure chronic ulcer of unspecified		L98.428 Non-pressure chronic ulcer of back with
	part of left lower leg with bone		other specified severity
	involvement without evidence of		L98.429 Non-pressure chronic ulcer of back with
	necrosis		unspecified severity
	L97.928 Non-pressure chronic ulcer of unspecified part of left lower leg with other specified	<mark>√6ª</mark> L98.49 I	Non-pressure chronic ulcer of skin of other sites
	severity		Non-pressure chronic ulcer of skin NOS
	L97.929 Non-pressure chronic ulcer of unspecified		L98.491 Non-pressure chronic ulcer of skin of other sites limited to breakdown of skin
	part of left lower leg with unspecified severity		L98.492 Non-pressure chronic ulcer of skin of other
	Seventy —		sites with fat layer exposed
L98 Other disorders classified	s of skin and subcutaneous tissue, not elsewhere		L98.493 Non-pressure chronic ulcer of skin of other
L98.Ø Pyogeni	ic granuloma RP		sites with necrosis of muscle L98.494 Non-pressure chronic ulcer of skin of other
EXCLUDE	pyogenic granuloma of gingiva (KØ6.8)	l '	sites with necrosis of bone
	pyogenic granuloma of maxillary alveolar ridge (KØ4.5)		.98.495 Non-pressure chronic ulcer of skin of other
DEE C	pyogenic granuloma of oral mucosa (K13.4)		sites with muscle involvement without
	olitary polypoid capillary hemangioma often associated ocal irritation, trauma, and superimposed inflammation.		evidence of necrosis 198.496 Non-pressure chronic ulcer of skin of other
	ed on the skin and gingival or oral mucosa, they bleed easily		sites with bone involvement without
and ma	ay ulcerate and form crusted sores.		evidence of necrosis
L98.1 Factitial			L98.498 Non-pressure chronic ulcer of skin of other
	tic excoriation		sites with other specified severity
	ES1 excoriation (skin-picking) disorder (F42.4)		L98.499 Non-pressure chronic ulcer of skin of other sites with unspecified severity
	2016,4Q,15 elf-inflicted skin lesions to satisfy an unconscious		
psycho	ological or emotional need. Methods used to injure the skin		
	e deep excoriations with a sharp instrument, scarification		
	knife, or the application of caustic chemicals and burning, imes with a cigarette.		
	neutrophilic dermatosis [Sweet]		
EJOIZ FEDITIE	neutrophine derinatosis (5weet)		

Manifestation

Q18.1 Preauricular sinus and cyst Cervicoaural fistula Fistula of auricle, congenital Q18.2 Other branchial cleft malformations RP Branchial cleft malformation NOS Cervical auricle Otocephaly Q18.3 Webbing of neck Pterygium colli **DEF:** Congenital malformation characterized by a thick, triangular skinfold that stretches from the lateral side of the neck across the shoulder. It is associated with genetic conditions such as Turner's and Noonan's syndromes. Q18.4 Macrostomia **DEF:** Rare congenital craniofacial bilateral or unilateral anomaly of the mouth due to malformed maxillary and mandibular processes. It results in an abnormally large mouth extending toward the ear. Q18.5 Microstomia Q18.6 Macrocheilia RP Hypertrophy of lip, congenital Q18.7 Microcheilia RP Q18.8 Other specified congenital malformations of face and RP Medial cyst of face and neck Medial fistula of face and neck

Congenital malformations of the circulatory system (Q2Ø-Q28)

Congenital anomaly NOS of face and neck

Q18.9 Congenital malformation of face and neck, unspecified

Q2Ø Congenital malformations of cardiac chambers and connections

EXCLUDES 1 dextrocardia with situs inversus (Q89.3)

mirror-image atrial arrangement with situs inversus (Q89.3)

Q2Ø.Ø Common arterial trunk

Persistent truncus arteriosus

Medial sinus of face and neck

EXCLUDES 1 aortic septal defect (Q21.4)

Q20.1 Double outlet right ventricle

Taussig-Bing syndrome

Q20.2 Double outlet left ventricle

Q20.3 Discordant ventriculoarterial connection

Dextrotransposition of aorta

Transposition of great vessels (complete)

Q20.4 Double inlet ventricle

Common ventricle

Cor triloculare biatriatum

Single ventricle

Q20.5 Discordant atrioventricular connection

Corrected transposition

Levotransposition

Ventricular inversion

Q20.6 Isomerism of atrial appendages

Isomerism of atrial appendages with asplenia or polysplenia

Q20.8 Other congenital malformations of cardiac chambers and connections

Cor binoculare

Q20.9 Congenital malformation of cardiac chambers and connections, unspecified


Q21 Congenital malformations of cardiac septa

EXCLUDES 1 acquired cardiac septal defect (I51.0)

Q21.Ø Ventricular septal defect


Roger's disease

Ventricular Septal Defect



Q21.1 Atrial septal defect

EXCLUDES 2 ostium primum atrial septal defect (type I) (Q21.20) AHA: 2022,4Q,39-40



021.10 Atrial septal defect, unspecified

Q21.11 Secundum atrial septal defect

Fenestrated atrial septum

Patent or persistent ostium secundum defect (type II)

Q21.12 Patent foramen ovale

Persistent foramen ovale

Q21.13 Coronary sinus atrial septal defect

Coronary sinus defect

Unroofed coronary sinus

Q21.14 Superior sinus venosus atrial septal defect

Superior vena cava type atrial septal defect

Inferior sinus venosus atrial septal defect 021.15

Inferior vena cava type atrial septal defect Q21.16 Sinus venosus atrial septal defect, unspecified

Sinus venosus defect, NOS

Q21.19 Other specified atrial septal defect

Common atrium

Other specified atrial septal abnormality

Appendix D: Skilled Nursing Facility Patient-Driven Payment Model

Skilled Nursing Facility Patient-Driven Payment Model

Payment Calculation Under PDPM

Payment under the Skilled Nursing Facility Patient-Driven Payment Model (PDPM) is based on the sum of six payment components. These include the following:

- Physical therapy
- · Occupational therapy
- · Speech-language pathology
- Nursing
- · Nontherapy ancillary
- Noncase-mix

The first five components are case-mix adjusted to capture the varied needs and characteristics of a resident's care. The sixth component is a noncase-mix component that covers utilization of resources that do not fluctuate according to patient characteristics.

The payment for each component is calculated by multiplying the case-mix index (CMI) for the resident's group, first by the component federal base payment rate, then by the specific day in the variable per diem adjustment schedule, when applicable. Additionally, for residents with HIV/AIDS indicated on their claim, the nursing portion of payment is multiplied by 1.18. These payments are then added, along with the noncase-mix component payment rate, to create a resident's total SNF PPS per diem rate under the PDPM.

Functional and Cognitive Scoring Under PDPM

Functional status, the ability to conduct certain activities, and cognitive function, the presence or absence of any sort of impairment in cognition, are two important patient characteristics for assessing the care needs of a resident. In the PDPM, this information is calculated using data from section GG of the Minimum Data Set (MDS) 3.0 which offers standardized, comprehensive measures of functional status and therapy needs. Functional scores are calculated for the physical therapy, occupational therapy, and nursing components.

Cognitive scores are used in the calculation of the SLP component. The PDPM Cognitive Score is based on the Cognitive Function Scale (CFS), which combines scores from a Brief Interview for Mental Status (BIMS) score and Cognitive Performance Scale (CPS) score.

Physical Therapy and Occupational Therapy Components

Both the physical therapy (PT) and occupational therapy (OT) components use a resident's PDPM clinical category and the resident's functional status to assign a resident to a PT/OT case-mix group (CMG).

PDPM Clinical Categories

SNF residents are classified based on the primary diagnosis for the SNF stay, using item 10020 on the MDS 3.0. The clinical classification may then be adjusted when the resident received a surgical intervention during the preceding hospital stay associated with that diagnosis. The provider must indicate the type of surgical procedure performed by selecting, as necessary, a surgical procedure category within item J2100 on the MDS 3.0. If the resident d not receive a related surgical procedure during the prior hospital stay, the resident may be categorized into a nonsurgical clinical category. Based on the provisions outlined above, the resident is classified into one of the following 10 clinical categories:

Surgical category:

- Major Joint Replacement or Spinal Surgery
- Nonorthopaedic Surgery
- Orthopedic Surgery (Except Major Joint Replacement or Spinal Surgery)

Nonsurgical category:

- Acute Neurologic
- Nonsurgical Orthopedic/Musculoskeletal
- · Medical Management
- · Acute Infections
- Cancer
- · Pulmonary
- · Cardiovascular and Coagulations

Collapsed Clinical Categories for PT and OT

Once CMS identified the default clinical categories as those being generally predictive of resource utilization in a SNF, they then undertook the necessary work to identify those categories predictive of PT and OT costs specifically. CMS found that the 10 inpatient clinical categories could be collapsed into four clinical categories, which predict varying degrees of PT and OT costs (see table 1).

Table 1. Collapsed Clinical Categories for PT and OT Classification

PDPM Clinical Category	Collapsed PT and OT Clinical Category
Major Joint Replacement or Spinal Surgery	Major Joint Replacement or Spinal Surgery
Non-Orthopedic Surgery Acute Neurologic	Non-Orthopedic Surgery and Acute Neurologic
Non-Surgical Orthopedic/Musculoskeletal Orthopedic Surgery (Except Major Joint Replacement or Spinal Surgery)	Other Orthopedic
Medical Management Acute Infections Cancer Pulmonary Cardiovascular and Coagulations	Medical Management

Functional Score for PT and OT

Regression analyses demonstrated that the resident's functional status is also predictive of PT and OT costs in addition to the resident's initial clinical categorization. CMS constructed a new functional score for PT and OT payment based on the newer, IMPACT Act compliant items from section GG of the MDS 3.0 (see table 2).

Table 2. Section GG Items Included in PT and OT Functional Measure

Table 2. Section Contents included in 1 and 0.1 ancetonal inclusive						
Section GG Item Number	Section GG Item Description					
GG0130A	Self-care: Eating					
GG0130B	Self-care: Oral hygiene					
GG0130C	Self-care: Toileting hygiene					
GG0170B	Mobility: Sit to lying					
GG0170C	Mobility: Lying to sitting on side of bed					
GG0170D	Mobility: Sit to stand					
GG0170E	Mobility: Chair/bed-to-chair transfer					
GG1070F	Mobility: Toilet transfer					
GG0170I	Mobility: Walk 10 feet					
GG0170J	Mobility: Walk 50 feet with 2 turns					
GG0170K	Mobility: Walk 150 feet					

PT and OT Case-Mix Groups

Under the PDPM, all residents are classified into one and only one of the 16 PT and OT case-mix groups for each of the two components.

These groups classify residents based on the two resident characteristics shown to be most predictive of PT and OT utilization: Clinical category and function score. CMS believes that these PT and OT case-mix groups better reflect relative resource use of clinically relevant resident subpopulations and therefore provide for more appropriate payment under the SNF PPS.

PT and OT case-mix classification groups:

TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP

Speech-Language Pathology Component

The speech-language pathology (SLP) component uses the resident's PDPM clinical category, cognitive function, the presence of an SLP-related comorbidity, and the presence of a swallowing disorder or mechanically altered diet to assign a resident to an SLP CMG.

PDPM Clinical Categories


CMS found only one clinical category predictive of increased SLP costs; the above criteria can be captured only if a resident is classified to the Acute Neurologic clinical category.

20 – Appendixes ICD-10-CM 2026


ICD-10-CM 2026 Illustrations

Chapter 6. Diseases of the Nervous System (GØØ-G99)

Brain



Cranial Nerves



ICD-10-CM 2026 Illustrations—9